Discover the latest about what's happening at CURE and in our community in the October 2018 CURE Update from Chief Scientific Officer, Laura Lubbers!
Pediatric Epilepsy
This study suggests that the risk of infantile spasms relapse in TSC may be reduced by high-dose vigabatrin treatment.
Learn why CBD may be an effective treatment for certain types of epilepsy, what risks can be associated with CBD, and what the FDA approval of means for the future of epilepsy research and treatment.
Fycompa received approval from the FDA for an indication expansion to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.
The risk of dying during pregnancy is negligible for the average Danish woman, but if the woman in question has epilepsy, the probability must be multiplied by five.
This short review summarizes the history of use of fenfluramine from the initial clinical observations followed by preclinical studies and subsequent successful clinical trial.
These preliminary data point to a favorable cognitive profile of brivaracetam similar to its precursor levetiracetam. Objective gains in attention and executive functions were accompanied by self-reported improvements in concentration and comprehension. Future studies with larger sample sizes and better control conditions are needed to confirm these findings.
Pediatric Epilepsy
Ovid Therapeutics Inc. announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies.
Pediatric Epilepsy
Neurelis, Inc. announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCOTM (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as cluster or acute repetitive seizures.
